IP Library › Granted Patent US 12,234,293
Granted Patent B2
US 12,234,293 · App. 17/846,950 · Granted Feb 25, 2025

Treatment for primary amyloidosis with anti-BCMA binding protein

Inventors: Sanjay Khandekar (Collegeville, PA); Patrick Mayes (Devon, PA); Joanna Opalinska (Collegeville, PA)
Assignee: GlaxoSmithKline Intellectual Property Development Limited
C07K16/2878A61K31/573A61K31/69A61K39/3955A61K39/39558A61K47/6817A61P35/00C07K16/2896C07K16/30C07K19/00A61K2039/505A61K2039/545C07K2317/56C07K2317/76C07K2317/92C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,293
App. No.
17/846,950
Granted
Feb 25, 2025
Kind
B2
Abstract

Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

Claims (19)

1. A method of treating primary amyloidosis (AL) in a subject in need thereof, the method comprising: administering to the subject in need thereof a dose of 1.9 mg/kg or 2.5 mg/kg of an anti-B-cell maturation antigen (BCMA) antibody conjugated to monomethyl auristatin F (MMAF), wherein the anti-BCMA antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:9 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:10.

2. The method of claim 1 , wherein 1.9 mg/kg of the anti-BCMA antibody conjugated to MMAF is administered to the subject in need thereof.

3. The method of claim 1 , wherein 2.5 mg/kg of the anti-BCMA antibody conjugated to MMAF is administered to the subject in need thereof.

4. The method of claim 1 further comprising administering to the subject in need thereof a proteasome inhibitor.

5. The method of claim 4 , wherein the proteasome inhibitor is bortezomib.

6. The method of claim 5 , wherein 1.3 mg/m 2 bortezomib is administered to the subject in need thereof.

7. The method of claim 6 , wherein 1.3 mg/m 2 bortezomib is administered to the subject in need thereof on days 1, 4, 8, and 11 of a 21-day cycle.

8. The method of claim 4 , wherein the proteasome inhibitor is carfilzomib.

9. The method of claim 4 , wherein the proteasome inhibitor is ixazomib.

10. The method of claim 4 , wherein the proteasome inhibitor is oprozomib.

11. A method of treating primary amyloidosis (AL) in a subject in need thereof, the method comprising: administering to the subject in need thereof (a) a dose of 1.9 mg/kg or 2.5 mg/kg of an anti-B-cell maturation antigen (BCMA) antibody conjugated to monomethyl auristatin F (MMAF), wherein the anti-BCMA antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:9 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:10, (b) a proteasome inhibitor, and (c) an anti-inflammatory compound.

12. The method of claim 11 , wherein 1.9 mg/kg of the anti-BCMA antibody conjugated to MMAF is administered to the subject in need thereof.

13. The method of claim 11 , wherein 2.5 mg/kg of the anti-BCMA antibody conjugated to MMAF is administered to the subject in need thereof.

14. The method of claim 11 , wherein the proteasome inhibitor is bortezomib.

15. The method of claim 14 , wherein 1.3 mg/m 2 of bortezomib is administered to the subject in need thereof.

16. The method of claim 15 , wherein 1.3 mg/m 2 of bortezomib is administered to the subject in need thereof on days 1, 4, 8, and 11 of a 21-day cycle.

17. The method of claim 11 , wherein the anti-inflammatory compound is dexamethasone.

18. The method of claim 17 , wherein 20 mg or 40 mg of dexamethasone is administered to the subject in need thereof.

19. The method of claim 18 , wherein 20 mg or 40 mg of dexamethasone is administered to the subject in need thereof on days 1, 2, 4, 5, 8, 9, 11, and 12 of a 21-day cycle.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 8, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073032/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2022
From: KHANDEKAR, SANJAY; MAYES, PATRICK; OPALINSKA, JOANNA
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 060279/0749 →
Continuity (3)
Division 16646836
Provisional Application 62558575 · Sep 14, 2017
Related Publication 20230019140A1 · Jan 19, 2023
References Cited (31)
US 9273141B2 · Algate et al. · 2016 [cited by applicant]
US 20130280280A1 · Algate et al. · 2013 [cited by applicant]
US 20140105915A1 · Algate et al. · 2014 [cited by applicant]
US 20160297885A1 · Kuo et al. · 2016 [cited by applicant]
US 20190352427A1 · Vu · 2019 [cited by examiner]
WO 2017093942A1 · 2017 [cited by applicant]
Driscoll et al. “Proteasome Inhibitors to Treat AL Amyloidosis”. Exploring New Findings on Amyloidosis, InTech, Aug. 24, 2016. Crossref, doi: 10.5772/63467. [cited by examiner]
Montes de Orca et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Mol Cancer Ther 20: 1941-1955, 2021. [cited by examiner]
Paul, William E., Fundamental Immunology, 3rd Edition, Raven Press, New York, Chapt. 8, pp. 292-295 (1993). [cited by examiner]
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci USA 79: 1979-1983, 1982. [cited by examiner]
Vasudevan et al. A single amino acid change in the binding pocket alters specificity of an anti-integrin antibody AP7.4 as revealed by its crystal structure. Blood Cells Mol Diseases 32: 176-181, 2004. [cited by examiner]
Zhang et al. Comprehensize optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. mAbs 7(1): 42-52, 2015. [cited by examiner]
Anonymous, “Study NCT03544281 on Date: May 23, 2018 (v1), To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethaso… [cited by applicant]
Podar et al., “Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma”, Expert Opinion on Pharmacotherapy, vol. 18, No. 11, pp. 1061-1079 (2017). [cited by applicant]
Tai et al., “Targeting B-cell maturation antigen in multiple myeloma”, Immunotherapy, Future Medicine, vol. 7, No. 11, pp. 1187-1199 (2015). [cited by applicant]
Alley et al., “Antibody-drug conjugates: targeted drug delivery for cancer,” Curr Opin Chem Biol 14: 529-537, 2010. [cited by applicant]
Brorson et al., “Mutational analysis of avidity and fine specificity of anti-levan antibodies,” J Immunol 163: 6694-6701, 1999. [cited by applicant]
Brummell et al., “Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residues,” Biochem 32(4): 1180-1187, 1993 (abstract). [cited by applicant]
Burks et al., “In vitro scanning saturation mutagenesis of an antibody binding pocket,” Proc Natl Acad Sci USA 94: 412-417, 1997. [cited by applicant]
Cohen et al., “First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma (M… [cited by applicant]
Colman et al., “Effects of amino acid sequence changes on antibody-antigen interactions,” Res Immunol 145: 33-36, 1994. [cited by applicant]
Dimopoulos et al., “Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study,” Lancet O… [cited by applicant]
Dolloff et al., “Emerging therapeutic strategies for overcoming proteasome inhibitor resistance,” Adv Cancer Res 127: 191-226, 2015. [cited by applicant]
Harrison et al., “The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit,” Am J Hematol 90: E86-E91, 2015. [cited by applicant]
Jang et al., “The structural basis for DNA binding by an anti-DNA autobody,” Mol Immunol 35: 1207-1217, 1998. [cited by applicant]
Kobayashi et al., “Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody,” Protein Engineering 12(10): 879-884, 1999. [cited by applicant]
Mohan et al., “Update on the optimal use of bortezomib in the treatment of multiple myeloma,” Cancer Management Res 9: 51-63, 2017. [cited by applicant]
Sutherland et al., “Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30 auristatin conjugates,” J Biol Chem 281(15): 10540-10547, 2006. [cited by applicant]
Tai et al., “Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of mutiple myeloma,” Blood 123(20): 3128-3138, 2014. [cited by applicant]
Bross et al., “Approval summary for bortezomib for injection in the treatment of multiple myeloma,” Clin. Cancer Res. 3954-3964 (2004). [cited by applicant]
Kamishohara et al., “Development of Novel Therapeutics for Multiple Myeloma and Improvement of Drug Lag,” Nippon Rinsho, vol. 74, Extra No. 5, (2016), pp. 585-591. [cited by applicant]